Clinical Financial Services (CFS), a specialty provider focused on the business and financial management activities for clinical trials, announces its new name and brand image. The company will now be known as CFS Clinical. The new image and name reflects the company’s rapid and continued growth and highlights its expanded service offerings.
CFS Clinical has two service areas within clinical trial business management: Contract and Regulatory Services and Global Payment Services which operate in unison to accelerate cycle times, manage compliance and risk and stimulate investigator relationships. To support these services, CFS Clinical has reinvented and revolutionized its technology platforms — CFS Startup InSite™ and CFS Payment InSite™ — both of which were unveiled at the DIA Conference.
According to Greg Seminack, President and Managing Partner of CFS Clinical, “Our new brand image captures what CFS Clinical is known for — transforming the business of clinical trials. It reinforces the fact that our ultimate goal is to empower biopharmaceutical and medical device companies worldwide to initiate and complete clinical trials quickly and efficiently, with better metrics and measurable ROI.” Mr. Seminack continues, “We are pleased to unveil our new identity and the continued investment in new service offerings that our new name conveys.”
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.